Effects of selective cyclooxygenase inhibitors on ischemia/reperfusion-induced hepatic microcirculatory dysfunction in mice

European Surgical Research

Volumn 35, Issue 5, 2003, Pages 408-416

  Ito, Yoshiya ^a,b   Katagiri, H ^a   Ishii, K ^a   Kakita, A ^a   Hayashi, I ^a   Majima, M ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

COX 1; COX 2; Microcirculation; Thromboxane; TNF

Indexed keywords

1 [7 (4 FLUOROPHENYL) 1,2,3,4 TETRAHYDRO 8 (4 PYRIDYL)PYRAZOLO[5,1 C][1,2,4]TRIAZIN 2 YL] 2 PHENYLETHANEDIONE; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DOMITROBAN; INDOMETACIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; OZAGREL; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; THROMBOXANE SYNTHASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ADHESION; CONTROLLED STUDY; DRUG EFFECT; ISCHEMIA; LEUKOCYTE; LIVER ISCHEMIA; MALE; MICROSCOPY; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY;

ALANINE TRANSAMINASE; ANIMALS; BICYCLO COMPOUNDS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; CYTOKINES; ENZYME INHIBITORS; FATTY ACIDS, MONOUNSATURATED; ISOENZYMES; LIVER; LIVER CIRCULATION; MALE; MEMBRANE PROTEINS; METHACRYLATES; MICE; MICE, INBRED C57BL; MICROCIRCULATION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; PYRIDINES; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; REPERFUSION INJURY; RNA, MESSENGER; THROMBOXANE-A SYNTHASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0042386436     PISSN: 0014312X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000072174     Document Type: Article

References (42)

1. Otto JC, Smith WL: Prostaglandin endoperoxidase synthases-1 and -2. J Lipid Mediat Cell Signal 1995;12:139-156.
2. Brzozowski T, Konturek PC, Konturek SJ, Sliwowski Z, Drozdowicz D, Stachura J, Pajdo R, Hahn EG: Role of prostaglandins generated by cyclooxygenase-1 and cyclooxygenase-2 in healing of ischemia-reperfusion-induced gastric lesions. Eur J Pharmacol 1999;385:47-61.
3. Nagayama M, Niwa K, Nagayama T, Ross ME, Iadecola C: The cyclooxygenase-2 inhibitor NS-398 ameliorates ischemic brain injury in wild-type mice but not in mice with deletion of the inducible nitric oxide synthase gene. J Cereb Blood Flow Metab 1999;19:1213-1219.
4. Sunose Y, Takeyoshi I, Ohwada S, Tsutsumi H, Iwazaki S, Kawata K, Kawashima Y, Tomizawa N, Matsumoto K, Morishita Y: The effect of cyclooxygenase-2 inhibitor FK3311 on ischemia-reperfusion injury in a canine total hepatic vascular exclusion model. J Am Coll Surg 2001;192:54-62.
5. Takeyoshi S, Sunose Y, Iwazaki S, Tsutsumi H, Aiba M, Kasahara M, Ohwada S, Matsumoto K, Morishita Y: The effect of a selective cyclooxygenase-2 inhibitor in extended liver resection with ischemia in dogs. J Surg Res 2001;100:25-31.
6. Menger MD, Vollmar B, Glasz J, Post S, Messmer K: Microcirculatory manifestations on hepatic ischemia/reperfusion injury; in Messmer K, Menger MD (eds): Liver Microcirculation and Hepatobiliary Function. Prog Appl Microcirc. Basel, Karger, 1993, vol 19, pp 106-124.
7. Vollmar B, Glasz J, Leiderer R, Post S, Menger MD: Hepatic microcirculatory perfusion failure is a determinant of liver dysfunction in warm ischemia-reperfusion. Am J Pathol 1994;145:1421-1431.
8. Futaki N, Yoshikawa K, Hamaska Y, Arai I, Higuchi S, Iizuka H, Otomo S: NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol 1993;24:105-110.
9. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, Anderson GD, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY, Isakson PC: Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-trifluoromethyl]-1H-pyrazol-1-yl)-benzenesulfonamide (SC-58635, celecoxib). J Med Chem 1997;40:1347-1365.
10. Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, Talley JJ, Masferrer JL, Seibert K, Isakson PC: Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA 1998;95:13313-13318.
11. Hanasaki K, Nagasaki T, Arita H: Characterization of platelet thromboxane A2/prostaglandin H2 receptor by a novel thromboxane receptor antagonist, [3H]S-145. Biochem Pharmacol 1989;38:2007-2017.
12. Yamamoto N, Sakai F, Yamazaki H, Nakahara K, Okuhara K: Effect of FR167653, a cytokine suppressive agent, on endotoxin-induced disseminated intravascular coagulation. Eur J Pharmacol 1996;314:137-142.
13. Vane JR, Bakhle S, Botting RM: Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120.
14. Lentsch AB, Yoshidome H, Cheadle WG, Miller FN, Edwards MJ: Chemokine involvement in hepatic ischemia/reperfusion injury in mice: Roles for macrophage inflammatory protein-2 and KC. Hepatology 1998;27:507-512.
15. Ishii K, Ito Y, Katagiri H, Matsumoto Y, Kakita A, Majima M: Neutrophil elastase inhibitor attenuates lipopolysaccharide-induced hepatic microvascular dysfunction in mice. Shock 2002;18:163-168.
16. Post S, Palma P, Rentsch M, Gonzalez MD, Menger MD: Hepatic reperfusion injury following cold ischemia in the rat: Potentials and quantitative analysis by in vivo fluorescence microscopy; in Messmer K, Menger MD (eds): Liver Microcirculation and Hepatobiliary Function. Prog Appl Microcirc. Basel, Karger, 1993, vol 19, pp 152-166.
17. Jaeschke H, Farhood A: Neutrophil and Kupffer cell-induced oxidant stress and ischemia-reperfusion injury in rat liver. Am J Physiol 1991;260:G355-G362.
18. Jaeschke H, Bautista AP, Spolarics Z, Spitzer JJ: Superoxide generation by Kupffer cells and priming of neutrophils during reperfusion after hepatic ischemia. Free Radic Res Commun 1991;15:277-284.
19. Jaeschke H: Reactive oxygen and ischemia/reperfusion injury of the liver. Chem Biol Interact 1991;79:115-136.
20. Rentsch M, Post S, Palma P, Lang G, Menger MD, Messmer K: Anti-ICAM-1 blockade reduces postsinusoidal WBC adherence following cold ischemia and reperfusion, but does not improve early graft function in rat liver transplantation. J Hepatol 2000;32:821-828.
21. Schauer RJ, Bilzer M, Kalmuk S, Gerbes AL, Leiderer R, Schildberg FW, Messmer K: Microcirculatory failure after rat liver transplantation is related to Kupffer cell-derived oxidant stress but not involved in early graft dysfunction. Transplantation 2001;72:1692-1699.
22. Bolli R, Shinmura K, Tang X-L, Kodani E, Xuan Y-T, Guo Y, Dawn B: Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res 2002;55:506-519.
23. Colletti LM, Remick DG, Burtch GD, Kunkel SL, Strieter RM, Campbell DA Jr: Role of tumor necrosis factor-alpha in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat. J Clin Invest 1990;85:1936-1943.
24. Horie Y, Wolf R, Russell J, Shanley TP, Granger DN: Role of Kupffer cells in gut ischemia/reperfusion-induced hepatic microvascular dysfunction in mice. Hepatology 1997;26:1499-1505.
25. Matsumoto Y, Ito Y, Hayashi I, Majima M, Ishii K, Katagiri H, Kakita A: Effect of FR167653, a novel inhibitor of tumor necrosis factor α and interleukin-1 β synthesis on lipopolysaccharide-induced hepatic microvascular dysfunction in mice. Shock 2002;17:411-415.
26. Bradham CA, Schemmer P, Stachlewitz RF, Thurman RG, Brenner DA: Activation of nuclear factor-kappaB during orthotopic liver transplantation in rats is protective and does not require Kupffer cells. Liver Transpl Surg 1999;5:282-293.
27. Rai RM, Loffreda S, Karp CL, Yang SQ, Lin HZ, Diehl AM: Kupffer cell depletion abolishes induction of interleukin-10 and permits sustained overexpression of tumor necrosis factor alpha messenger RNA in the regenerating rat liver. Hepatology 1997;25:889-895.
28. Lentsch AB, Kato A, Yoshidome H, McMasters KM, Edwards MJ: Inflammatory mechanisms and therapeutic strategies for warm hepatic ischemia/reperfusion injury. Hepatology 2000;32:169-173.
29. Mack Strong VE, Mackrell PJ, Concannon EM, Mestre JR, Smyth GP, Schaefer PA, Stapleton PP, Daly JM: NS-398 treatment after trauma modifies NF-κB activation and improves survival. J Surg Res 2001;98:40-46.
30. Grandel U, Fink L, Blum A, Heep M, Buerke M, Kraemer H-J, Mayer K, Bohle RM, Seeger W, Grimminger F, Sibelius U: Endotoxin-induced myocardial tumor necrosis factor-α synthesis depresses contractility of isolated rat hearts. Evidence for a role of sphingosine and cyclooxygenase-2-derived thromboxane production. Circulation 2000;102:2758-2764.
31. Wanner GA, Müller P, Ertel W, Busch CJ, Menger MD, Messmer K: Different effect of cyclooxygenase metabolites on proinflammatory cytokine release by Kupffer cells after liver ischemia and reperfusion. Am J Surg 1998;175:146-151.
32. 2 activity during warm ischemia of the liver. J Surg Res 1996;61:103-107.
33. 2 inhibitor in liver ischemia. Hepatogastroenterology 1998;45:1781-1786.
34. 2 in nonadherent human monocytes. J Immunol 1997;158:351-358.
35. Fitzgerald GA, Pederson AK, Patrono C: Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 1983;67:1174-1177.
36. 2 production in human monocytes: Implication for the use of cyclooxygenase inhibitors. J Immunol 2000;165:1605-1611.
37. Tilley SL, Coffman TM, Koller BH: Mixed messages: Modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest 2001;108:15-23.
38. Post S, Goerig M, Otto G, Manner M, Foltis C, Hofmann W, Herfarth C: Rapid increase in the activity of enzymes of eicosanoid synthesis in hepatic and extrahepatic tissues after experimental liver transplantation. Transplantation 1991;51:1058-1064.
39. Takeyoshi I, Otani Y, Koibuchi Y, Yokoe T, Iino Y, Matsumoto K, Muramoto M, Satoh S, Morishita Y: Effects of FR167653 on pulmonary ischemia-reperfusion injury: Administration timing. Transplant Proc 1999;31:1935-1936.
40. Otani Y, Takeyoshi I, Koibuchi Y, Matsumoto K, Muramoto M, Morishita Y: The effect of FR167653 on pulmonary ischemia-reperfusion injury in rats. J Heart Lung Transplant 2000;19:377-383.
41. Lee JC, Laydon JT, McDonnel PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, et al: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372:739-746.
42. Teoh N, Dela Pena A, Farrell G: Hepatic ischemic preconditioning in mice is associated with activation of NF-κB, p38 kinase, and cell cycle entry. Hepatology 2002;36:94-102.